In a new deal with Alloy Therapeutics, Biogen—the makers of Leqembi—is investing in RNA technology that could point toward what comes next in Alzheimer’s care.
Could Leqembi be given faster and more easily in the future? The new Biogen–Alteogen deal suggests it’s possible—but it doesn’t confirm changes to Leqembi. Here’s what professionals and families should understand.
The diagnostic and treatment network behind Leqembi may be its biggest competitive edge.
New research reveals that Leqembi’s Fc region switches on microglia — the brain’s immune cells — helping them clear toxic amyloid. Here’s why that mechanism matters for treatment and safety.
A safer Alzheimer’s treatment may be on the horizon — but families still have meaningful choices today.
Many diagnosed patients won’t qualify — here are the
7 medical criteria.
New early-onset Alzheimer’s data show that lecanemab can slow functional decline—even while tau continues to spread in the brain. The research helps explain how amyloid-lowering treatments may still preserve daily life, despite the disease’s complexity.
In a one-hour seminar, a leading neurologist answers the most important questions families ask about what these new therapies can realistically deliver — from effectiveness and safety to eligibility, infusion logistics, cost, and access.
New evidence suggests genetics—not geography—may explain why Leqembi causes fewer ARIA brain side effects in parts of Asia, and what that means for families everywhere.
Alzheimer’s treatment eligibility may be far larger than previously thought. A major Nature study using blood tests suggests millions more older adults could qualify for treatment than current use reflects. As diagnosis becomes easier, demand for drugs like Leqembi could shift sharply.
MCT oil for dementia remains closely followed—and increasingly researched. Skepticism has been part of this conversation from the start, given how dietary approaches can be overhyped. That’s why updated 2025–2026 studies are worth a fresh look.
“Alive Inside” is a fascinating movie on music bridging past and present in dementia. Katie Couric talks with the personalities behind this breakthrough film.
In a new deal with Alloy Therapeutics, Biogen—the makers of Leqembi—is investing in RNA technology that could point toward what comes next in Alzheimer’s care.
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
TEEPA CARE VIDEO: Learn about Alzheimer’s 6 stages. Teepa Snow shows what to expect, while keeping the focus on the person for whom you care.
Melvyn Amrine may not have remembered the details of his life since his Alzheimer’s diagnosis, but he sure proved that his love for his wife transcended memory.
No spam, only news and updates.
